Lecanemab in patients with early alzheimer’s disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study

HIGHLIGHTS

• who: Eric McDade from the The DIAN-TU, Department of Neurology, Washington University School of Medicine, StLouis, MO, USA have published the paper: Lecanemab in patients with early Alzheimeru2019s disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study, in the Journal: (JOURNAL) of 17/Nov/2022
• what: The aim of this analysis is to report results from study 201 blinded period (core) the open-label extension (OLE) and gap period (between core and OLE) supporting the effectiveness of lecanemab. In . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.